You just read:

Novartis Therapy Gilenya™ Reduced the Risk of MS Disability Progression Regardless of Treatment History or Disease Severity, New Analysis Shows

News provided by

Novartis Pharmaceuticals Corporation

Apr 11, 2011, 01:30 ET